<p>Corcept Therapeutics（納斯達克：CORT - 獲取免費報告）在週一發佈給投資者的研究報告中，被 Zacks Research 的股票分析師從 “強烈賣出” 評級上調至 “持有” 評級，Zacks.com 報道。</p>
<ul>
<li>3 只生物製藥股票逆勢上漲</li>
</ul>
<p>其他幾位分析師也對 CORT 發佈了報告。Truist Financial 在 3 月 25 日的研究報告中將 Corcept Therapeutics 的評級上調至 “強烈買入”。Canaccord Genuity Group 在 3 月 26 日的研究報告中將 Corcept Therapeutics 的目標股價從 100.00 美元上調至 110.00 美元，並給予該股票 “買入” 評級。Wolfe Research 在 3 月 26 日的研究報告中將 Corcept Therapeutics 的評級從 “表現不佳” 上調至 “同業表現”。Piper Sandler 在週五將 Corcept Therapeutics 的目標股價從 73.00 美元上調至 88.00 美元，並給予該股票 “增持” 評級。最後，HC Wainwright 在週一將 Corcept Therapeutics 的目標股價從 60.00 美元上調至 75.00 美元，並給予該股票 “買入” 評級。一位分析師給予該股票 “強烈買入” 評級，三位分析師給予 “買入” 評級，四位分析師給予 “持有” 評級。根據 MarketBeat 的數據，該公司的平均評級為 “適度買入”，共識目標價為 74.67 美元。</p>
<p>獲取 <strong>Corcept Therapeutics</strong> 的提醒：</p>
<p><strong>查看我們關於 Corcept Therapeutics 的最新報告</strong></p>
<h2>Corcept Therapeutics 股票下跌 0.5%</h2>
<p>CORT 週一開盤價為 51.37 美元。該公司的 50 日簡單移動平均線為 39.47 美元，200 日簡單移動平均線為 54.18 美元。Corcept Therapeutics 的 52 周低點為 28.66 美元，52 周高點為 91.00 美元。該股票的市值為 55.1 億美元，市盈率為 146.76，貝塔值為 0.36。</p>
<p>Corcept Therapeutics（納斯達克：CORT - 獲取免費報告）在 4 月 30 日最後發佈了季度財報。這家生物技術公司報告季度每股收益（EPS）為（0.30）美元，低於共識預期的（0.11）美元，差距為（0.19）美元。該公司季度收入為 1.649 億美元，而共識預期為 1.8583 億美元。Corcept Therapeutics 的股本回報率為 7.40%，淨利潤率為 6.14%。該公司季度收入同比增長 4.9%。去年同期，該公司每股收益為 0.17 美元。整體來看，股票分析師預計 Corcept Therapeutics 在當前年度將發佈 0.35 美元的每股收益。</p>
<h2>內部活動</h2>
<p>在其他 Corcept Therapeutics 的新聞中，董事 G Leonard Baker, Jr.在 3 月 17 日的交易中購買了 100,000 股該公司的股票。該股票的平均購買價格為每股 33.14 美元，總價值為 3,314,000.00 美元。完成購買後，該董事直接持有 1,146,631 股該公司的股票，價值約為 37,999,351.34 美元。此次交易使其持股增加了 9.55%。該購買在 SEC 的備案中披露，相關信息可通過此鏈接獲取。此外，首席執行官 Joseph K. Belanoff 在 3 月 25 日的交易中出售了 26,198 股 Corcept Therapeutics 的股票。該股票的平均售價為 50.07 美元，總交易額為 1,311,733.86 美元。出售完成後，首席執行官在公司中持有 2,918,326 股，價值約為 146,120,582.82 美元。此次交易使其持股減少了 0.89%。該出售的披露信息可在 SEC 備案中找到。在過去三個月中，內部人士共出售了 66,198 股公司股票，價值為 2,851,169 美元。公司內部人士持有 20.70% 的公司股票。</p>
<h2>機構投資者對 Corcept Therapeutics 的看法</h2>
<p>機構投資者和對沖基金最近調整了對該股票的持有。Torren Management LLC 在第四季度購買了 Corcept Therapeutics 的新頭寸，價值約為 25,000 美元。Advisory Services Network LLC 在第三季度購買了 Corcept Therapeutics 的新股份，價值約為 25,000 美元。Clearstead Advisors LLC 在第三季度將其在 Corcept Therapeutics 的持倉增加了 163.6%。Clearstead Advisors LLC 現在持有 311 股該生物技術公司的股票，價值為 26,000 美元，此前在上個季度又購買了 193 股。Atlas Capital Advisors Inc.在第四季度購買了 Corcept Therapeutics 的新股份，價值約為 31,000 美元。最後，Hantz Financial Services Inc.在第四季度將其在 Corcept Therapeutics 的持倉增加了 113.7%。Hantz Financial Services Inc.現在持有 985 股該生物技術公司的股票，價值 34,000 美元，此前在此期間又購買了 524 股。93.61% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>關於 Corcept Therapeutics</h2>
<p>（獲取免費報告）</p>
<p>Corcept Therapeutics 是一家臨牀階段的生物製藥公司，專注於發現和開發調節皮質醇作用的藥物，皮質醇是一種與多種嚴重代謝、腫瘤和精神疾病相關的激素。該公司的科學平台專注於選擇性靶向糖皮質激素受體，以抵消過量皮質醇的有害後果，這一策略旨在解決具有顯著未滿足醫療需求的疾病。</p>
<p>該公司的旗艦上市產品 Korlym（米非司酮）已在美國獲得批准，用於治療因庫欣綜合症引起的高血糖，適用於患有 2 型糖尿病或葡萄糖耐受不良且不適合手術的患者。</p>
<h2>另見</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Corcept Therapeutics</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q09SVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q09SVA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1000 美元在 Corcept Therapeutics 嗎？</h2>
<p>在考慮 Corcept Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Corcept Therapeutics 並不在名單上。</p>
<p>雖然 Corcept Therapeutics 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Corcept醫療

醫療業 ETF - SPDR

標普生物技術 3 倍做多 - Direxion

<p>Zacks Research 將 Corcept Therapeutics (NASDAQ:CORT) 的評級從 “強烈賣出” 上調至 “持有”。其他分析師也提高了他們的評級，Truist Financial 給出了 “強烈買入” 的評級，而 Canaccord Genuity 將目標價格從 100 美元上調至 110 美元。該股票開盤價為 51.37 美元，市值為 55.1 億美元。Corcept 報告的季度每股收益為（0.30 美元），未達到預期，但收入同比增長 4.9%。內部交易活動包括董事 G Leonard Baker, Jr. 的大額購買和首席執行官 Joseph K. Belanoff 的出售</p>

<p>Corcept Therapeutics (NASDAQ:CORT - Get Free Report) was upgraded by stock analysts at Zacks Research from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research note issued to investors on Monday,Zacks.com reports.</p>
<div class="lb-trans"><p>Corcept Therapeutics（納斯達克：CORT - 獲取免費報告）在週一發佈給投資者的研究報告中，被 Zacks Research 的股票分析師從 “強烈賣出” 評級上調至 “持有” 評級，Zacks.com 報道。</p>
</div><ul>
<li>3 Biopharmaceutical Stocks Bucking the Sell-Off</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只生物製藥股票逆勢上漲</li>
</ul>
</div><p>Several other analysts have also issued reports on CORT. Truist Financial raised Corcept Therapeutics to a &#34;strong-buy&#34; rating in a research note on Wednesday, March 25th. Canaccord Genuity Group lifted their price target on shares of Corcept Therapeutics from $100.00 to $110.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, March 26th. Wolfe Research raised shares of Corcept Therapeutics from an &#34;underperform&#34; rating to a &#34;peer perform&#34; rating in a research note on Thursday, March 26th. Piper Sandler boosted their price target on shares of Corcept Therapeutics from $73.00 to $88.00 and gave the stock an &#34;overweight&#34; rating in a research note on Friday. Finally, HC Wainwright raised their price target on shares of Corcept Therapeutics from $60.00 to $75.00 and gave the stock a &#34;buy&#34; rating in a report on Monday. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and four have given a Hold rating to the company's stock. According to MarketBeat, the company currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $74.67.</p>
<div class="lb-trans"><p>其他幾位分析師也對 CORT 發佈了報告。Truist Financial 在 3 月 25 日的研究報告中將 Corcept Therapeutics 的評級上調至 “強烈買入”。Canaccord Genuity Group 在 3 月 26 日的研究報告中將 Corcept Therapeutics 的目標股價從 100.00 美元上調至 110.00 美元，並給予該股票 “買入” 評級。Wolfe Research 在 3 月 26 日的研究報告中將 Corcept Therapeutics 的評級從 “表現不佳” 上調至 “同業表現”。Piper Sandler 在週五將 Corcept Therapeutics 的目標股價從 73.00 美元上調至 88.00 美元，並給予該股票 “增持” 評級。最後，HC Wainwright 在週一將 Corcept Therapeutics 的目標股價從 60.00 美元上調至 75.00 美元，並給予該股票 “買入” 評級。一位分析師給予該股票 “強烈買入” 評級，三位分析師給予 “買入” 評級，四位分析師給予 “持有” 評級。根據 MarketBeat 的數據，該公司的平均評級為 “適度買入”，共識目標價為 74.67 美元。</p>
</div><p>Get <strong>Corcept Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Corcept Therapeutics</strong> 的提醒：</p>
</div><p><strong>View Our Latest Report on Corcept Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 Corcept Therapeutics 的最新報告</strong></p>
</div><h2>Corcept Therapeutics Stock Down 0.5%</h2>
<div class="lb-trans"><h2>Corcept Therapeutics 股票下跌 0.5%</h2>
</div><p>CORT opened at $51.37 on Monday. The business's fifty day simple moving average is $39.47 and its 200 day simple moving average is $54.18. Corcept Therapeutics has a 52 week low of $28.66 and a 52 week high of $91.00. The stock has a market cap of $5.51 billion, a PE ratio of 146.76 and a beta of 0.36.</p>
<div class="lb-trans"><p>CORT 週一開盤價為 51.37 美元。該公司的 50 日簡單移動平均線為 39.47 美元，200 日簡單移動平均線為 54.18 美元。Corcept Therapeutics 的 52 周低點為 28.66 美元，52 周高點為 91.00 美元。該股票的市值為 55.1 億美元，市盈率為 146.76，貝塔值為 0.36。</p>
</div><p>Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.19). The firm had revenue of $164.90 million for the quarter, compared to the consensus estimate of $185.83 million. Corcept Therapeutics had a return on equity of 7.40% and a net margin of 6.14%.The company's revenue for the quarter was up 4.9% on a year-over-year basis. During the same period last year, the firm earned $0.17 EPS. As a group, equities analysts anticipate that Corcept Therapeutics will post 0.35 earnings per share for the current year.</p>
<div class="lb-trans"><p>Corcept Therapeutics（納斯達克：CORT - 獲取免費報告）在 4 月 30 日最後發佈了季度財報。這家生物技術公司報告季度每股收益（EPS）為（0.30）美元，低於共識預期的（0.11）美元，差距為（0.19）美元。該公司季度收入為 1.649 億美元，而共識預期為 1.8583 億美元。Corcept Therapeutics 的股本回報率為 7.40%，淨利潤率為 6.14%。該公司季度收入同比增長 4.9%。去年同期，該公司每股收益為 0.17 美元。整體來看，股票分析師預計 Corcept Therapeutics 在當前年度將發佈 0.35 美元的每股收益。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>內部活動</h2>
</div><p>In other Corcept Therapeutics news, Director G Leonard Baker, Jr. purchased 100,000 shares of the company's stock in a transaction that occurred on Tuesday, March 17th. The stock was bought at an average price of $33.14 per share, with a total value of $3,314,000.00. Following the completion of the purchase, the director directly owned 1,146,631 shares of the company's stock, valued at $37,999,351.34. The trade was a 9.55% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Joseph K. Belanoff sold 26,198 shares of Corcept Therapeutics stock in a transaction on Wednesday, March 25th. The shares were sold at an average price of $50.07, for a total transaction of $1,311,733.86. Following the completion of the sale, the chief executive officer owned 2,918,326 shares in the company, valued at approximately $146,120,582.82. This trade represents a 0.89% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 66,198 shares of company stock valued at $2,851,169. Company insiders own 20.70% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Corcept Therapeutics 的新聞中，董事 G Leonard Baker, Jr.在 3 月 17 日的交易中購買了 100,000 股該公司的股票。該股票的平均購買價格為每股 33.14 美元，總價值為 3,314,000.00 美元。完成購買後，該董事直接持有 1,146,631 股該公司的股票，價值約為 37,999,351.34 美元。此次交易使其持股增加了 9.55%。該購買在 SEC 的備案中披露，相關信息可通過此鏈接獲取。此外，首席執行官 Joseph K. Belanoff 在 3 月 25 日的交易中出售了 26,198 股 Corcept Therapeutics 的股票。該股票的平均售價為 50.07 美元，總交易額為 1,311,733.86 美元。出售完成後，首席執行官在公司中持有 2,918,326 股，價值約為 146,120,582.82 美元。此次交易使其持股減少了 0.89%。該出售的披露信息可在 SEC 備案中找到。在過去三個月中，內部人士共出售了 66,198 股公司股票，價值為 2,851,169 美元。公司內部人士持有 20.70% 的公司股票。</p>
</div><h2>Institutional Investors Weigh In On Corcept Therapeutics</h2>
<div class="lb-trans"><h2>機構投資者對 Corcept Therapeutics 的看法</h2>
</div><p>Institutional investors and hedge funds have recently modified their holdings of the stock. Torren Management LLC purchased a new position in shares of Corcept Therapeutics during the fourth quarter valued at about $25,000. Advisory Services Network LLC purchased a new stake in Corcept Therapeutics in the third quarter worth about $25,000. Clearstead Advisors LLC boosted its position in Corcept Therapeutics by 163.6% during the 3rd quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company's stock valued at $26,000 after acquiring an additional 193 shares in the last quarter. Atlas Capital Advisors Inc. bought a new stake in Corcept Therapeutics during the 4th quarter valued at approximately $31,000. Finally, Hantz Financial Services Inc. grew its holdings in shares of Corcept Therapeutics by 113.7% during the 4th quarter. Hantz Financial Services Inc. now owns 985 shares of the biotechnology company's stock worth $34,000 after acquiring an additional 524 shares during the period. 93.61% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>機構投資者和對沖基金最近調整了對該股票的持有。Torren Management LLC 在第四季度購買了 Corcept Therapeutics 的新頭寸，價值約為 25,000 美元。Advisory Services Network LLC 在第三季度購買了 Corcept Therapeutics 的新股份，價值約為 25,000 美元。Clearstead Advisors LLC 在第三季度將其在 Corcept Therapeutics 的持倉增加了 163.6%。Clearstead Advisors LLC 現在持有 311 股該生物技術公司的股票，價值為 26,000 美元，此前在上個季度又購買了 193 股。Atlas Capital Advisors Inc.在第四季度購買了 Corcept Therapeutics 的新股份，價值約為 31,000 美元。最後，Hantz Financial Services Inc.在第四季度將其在 Corcept Therapeutics 的持倉增加了 113.7%。Hantz Financial Services Inc.現在持有 985 股該生物技術公司的股票，價值 34,000 美元，此前在此期間又購買了 524 股。93.61% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>About Corcept Therapeutics</h2>
<div class="lb-trans"><h2>關於 Corcept Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company's scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.</p>
<div class="lb-trans"><p>Corcept Therapeutics 是一家臨牀階段的生物製藥公司，專注於發現和開發調節皮質醇作用的藥物，皮質醇是一種與多種嚴重代謝、腫瘤和精神疾病相關的激素。該公司的科學平台專注於選擇性靶向糖皮質激素受體，以抵消過量皮質醇的有害後果，這一策略旨在解決具有顯著未滿足醫療需求的疾病。</p>
</div><p>The company's flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing's syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.</p>
<div class="lb-trans"><p>該公司的旗艦上市產品 Korlym（米非司酮）已在美國獲得批准，用於治療因庫欣綜合症引起的高血糖，適用於患有 2 型糖尿病或葡萄糖耐受不良且不適合手術的患者。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Corcept Therapeutics</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Corcept Therapeutics</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q09SVA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=CORT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Corcept Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 Corcept Therapeutics 嗎？</h2>
</div><p>Before you consider Corcept Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Corcept Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corcept Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Corcept Therapeutics 並不在名單上。</p>
</div><p>While Corcept Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Corcept Therapeutics 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Corcept Therapeutics (NASDAQ:CORT) Upgraded by Zacks Research to Hold Rating

Market Beat

2 倍做多納斯達克生物技術 ETF - ProShares

納斯達克生物科技指數 ETF - iShares Nasdaq

醫藥突破 ETF - ALPS

美國制藥 ETF - iShares

紐交所高增長板生物技術指數 ETF - First Trust

標普生物技術 ETF - SPDR

標普全球醫療股指數 ETF - iShares

生物科技 ETF - VanEck Vectors

基因改革 ETF - ARK

醫療業 ETF - Vanguard

動態生物技術與基因組 ETF - Invesco

Corcept Therapeutics（納斯達克股票代碼：CORT）被 Zacks Research 上調至持有評級